The endorsement is the agency's first through the Human Variant Database Program, for which it released final guidance earlier this year.

Following promising data from its Circulating Cell-free Genome Atlas study, the firm decided to pivot its breast cancer trial to support its multi-cancer test.

The guidance addresses cases in which there's enough evidence to conclude that the CDx is suitable for use with a specific group or class of oncology therapies.

The CDx would guide use of Novartis' BYL719 (alpelisib) in combination with fulvestrant for men and postmenopausal women with HR+/HER2- breast cancer.

The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.

Dec
06
Sponsored by
MNG Laboratories

Join MNG Laboratories' Chief Medical Officer, Dr. Peter L. Nagy, and the Clinical Reporting Team as they present multiple case studies illustrating the value of using complementary testing and data analysis methods to increase the clinical sensitivity of MNG’s genetic testing portfolio. The team will highlight cases solved through the application of high resolution CNV assessment, mitochondrial DNA analysis, transcriptome/RNA sequencing, and repeat expansion screening from genome sequencing datasets. After the presentation, there will be a 15 minute Q&A with our speakers. 

Breakthrough UV-C Performance Enables Better Control for Lab Managers

This white paper makes the case for why UV LED technology deserves serious consideration by RNA sequencing labs for controlling ribonuclease in a laboratory setting. It describes Phoseon’s findings related to LED light engines for the inactivation of RNases in a laboratory setting.

Clinical laboratories are increasingly adopting molecular assays as an alternative to the tedious, time-consuming stool cultures that have long been the mainstay for testing patients who might have infectious diarrhea or conditions such as Salmonella or Campylobacter. With an estimated 1.7 billion cases of childhood diarrheal disease occurring annually around the world, this is a significant advance for gastroenteritis testing.